Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2022

View Archived Issues

Senescent neurons block neurogenesis in mice

SpFN vaccine confers protection in nonhuman primates against SARS-CoV-2

New TRPA1 antagonists discovered at Boehringer Ingelheim

New macrophage migration inhibitory factor inhibitors identified at Immunophage Biomedical

Scripps Research Institute, ShangPharma Innovation patent Rev-erbA-alpha/beta agonists

New three-prime repair exonuclease 1 inhibitors described by Tempest Therapeutics

Gene silencing using Toc-HDO technology ameliorated symptoms in EAE models

Researchers develop novel murine model of age-related macular degeneration

Targeting HO-1 signaling pathway against dengue hemorrhagic fever

Alpha Tau enters sponsored research agreement with MD Anderson to study Alpha DaRT in breast cancer

4E Therapeutics discloses new MNK1 and/or MNK2 inhibitors

Macolacin, a novel naturally inspired antibiotic with efficacy against MDR pathogens

Alzinova selects humanized lead candidate of monoclonal antibody ALZ-201

M1 muscarinic receptor mutant mice show accelerated prion neurodegeneration

Tevogen to study allogeneic T-cell technology for Epstein-Barr virus and MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...